explore -WSS

explore

author：knowledge 2025-10-01 00:14:25 - browse：17

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： In diabetes hearing, Sanders takes on a new foe: food makers

entertainment

Wikipedia

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Pharma patents targeted by Biden in move to slash drug prices

Americans' trust in science, scientist continues decline: Report

How to ethically and practically extend health care to all

Congenital heart disease patients face new threat of heart failure

H.R. 3 is the wrong path to lower drug costs

focus

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Group behind ProMed defends move to subscription

New air purifier tech could be key to improving indoor air quality

Teach medical students about patients with intellectual disabilities

Jerome Adams on the need for new antivirals for Covid

In diabetes hearing, Sanders takes on a new foe: food makers

The cancer drug shortage isn’t new — and neither are the solutions

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medicare proposal to cover medical devices draws a mixed reaction

Congenital heart disease patients face new threat of heart failure

knowledge

SCOTUS to consider access to abortion pill mifepristone

H.R. 3 is the wrong path to lower drug costs

FDA scientists endorse Pfizer/BioNTech Covid

Pharma patents targeted by Biden in move to slash drug prices

How I helped Pfizer think through the ethics of Viagra

CDC recommends RSV monoclonal antibody for infants

Wikipedia

entertainment

Wikipedia

leisure time